North Carolina

Who we are

  • April 5, 2022
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
  • April 5, 2022
    A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
  • April 5, 2022
    A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
  • April 5, 2022
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
  • April 5, 2022
    A Study of NX-1607 in Adults With Advanced Malignancies
  • April 5, 2022
    A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
  • April 5, 2022
    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
  • April 5, 2022
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
  • January 1, 1970
    A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors